- Home
- AGL vs PHVS Comparison
AGL vs PHVS Comparison
Compare AGL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | PHVS |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4M | 1.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGL | PHVS |
|---|---|---|
| Price | $0.68 | $26.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $2.77 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 6.1M | 304.3K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,885,571,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $0.51 | $11.51 |
| 52 Week High | $6.08 | $29.80 |
Technical Indicators
Market Signals| Indicator | AGL | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 53.12 |
| Support Level | $0.67 | $25.27 |
| Resistance Level | $0.75 | $26.09 |
| Average True Range (ATR) | 0.04 | 1.35 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 22.45 | 53.94 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.